Brokerages Set Travere Therapeutics, Inc. (NASDAQ:TVTX) PT at $15.58

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $15.58.

Several research firms have weighed in on TVTX. Wedbush restated an “outperform” rating and set a $13.00 target price on shares of Travere Therapeutics in a research note on Wednesday, April 17th. Canaccord Genuity Group upped their price objective on shares of Travere Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Guggenheim reissued a “neutral” rating on shares of Travere Therapeutics in a research note on Wednesday, March 27th. Finally, HC Wainwright reiterated a “buy” rating and set a $19.00 price objective on shares of Travere Therapeutics in a research report on Tuesday, May 7th.

Travere Therapeutics Stock Up 0.1 %

NASDAQ TVTX opened at $9.80 on Monday. The company has a market cap of $746.07 million, a price-to-earnings ratio of -4.67 and a beta of 0.77. Travere Therapeutics has a 1-year low of $5.12 and a 1-year high of $17.57. The company has a current ratio of 2.78, a quick ratio of 2.75 and a debt-to-equity ratio of 5.10. The company has a 50 day moving average of $7.38 and a 200-day moving average of $7.72.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings data on Monday, May 6th. The company reported ($1.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.78). The firm had revenue of $41.40 million for the quarter, compared to analyst estimates of $43.46 million. Travere Therapeutics had a negative return on equity of 238.06% and a negative net margin of 87.94%. The company’s quarterly revenue was up 34.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.27) earnings per share. On average, equities research analysts expect that Travere Therapeutics will post -3.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Travere Therapeutics

Several institutional investors have recently made changes to their positions in TVTX. SG Americas Securities LLC purchased a new stake in shares of Travere Therapeutics in the second quarter worth about $139,000. Talbot Financial LLC purchased a new position in Travere Therapeutics during the second quarter worth about $522,000. Bayesian Capital Management LP purchased a new position in shares of Travere Therapeutics during the first quarter worth about $177,000. Price T Rowe Associates Inc. MD increased its position in shares of Travere Therapeutics by 10.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 31,009 shares of the company’s stock worth $240,000 after purchasing an additional 2,948 shares during the last quarter. Finally, Affinity Asset Advisors LLC purchased a new stake in Travere Therapeutics in the first quarter valued at approximately $964,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.